Chidiebere F. Uchechukwu

Chidiebere F. Uchechukwu

Auto-generated profile, based on publicly available information

Chidiebere F. Uchechukwu

Warwick Medical School, Gibbet Hill Campus, University of Warwick, Coventry, Cv47al, United Kingdom

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2024 in Journal of Medical Microbiology
Verified
Journal Article
Open access
CUChidiebere F. Uchechukwu
Chidiebere F. Uchechukwu
ASAdedayo Shonekan
Adedayo Shonekan
Recently, bacteriophages have been considered alternatives to antibacterial treatments. Infectious diseases continue to plague the world because bacteria can adapt and develop defence mechanisms against antibiotics. The growing incidence of antibiotic-resistant bacterial infections necessitated the development of new techniques for treating bacterial infections worldwide. Clinical trials have shown efficiency against antibiotic-resistant bacteria. However, scientists in future clinical trials should scrutinize phage resistance implications, assess combination strategies with antimicrobial agents and address challenges in phage therapy delivery for effective implementation.

25 September 2025 in Microbiology and Molecular Biology Reviews
Verified
Journal Article
Closed access
CUChidiebere F. Uchechukwu
Chidiebere F. Uchechukwu
NRNicole C. Robb
Nicole C. Robb
SUMMARY: Pleomorphism in influenza viruses, characterized by diverse morphological forms ranging from spherical virions to elongated filaments, has been suggested to present significant implications for pathogenesis. This review examines the role of pleomorphism on the influenza virus life cycle, encompassing viral attachment and entry, replication, assembly, and budding, as well as transmission dynamics. It explores the determinants' underlying morphological variability in virions and their impact on viral fitness and host interactions. Insights into how pleomorphic forms of the virus influence disease severity and the efficacy of antivirals are discussed. Understanding the implications of pleomorphism in influenza virus pathogenesis is crucial for the development of effective disease prevention, control, and treatment strategies.

10 October 2023 in Journal of General Virology
Verified
Journal Article
Open access
CUChidiebere F. Uchechukwu
Chidiebere F. Uchechukwu
UAUchechukwu Love Anyaduba
Uchechukwu Love Anyaduba
CUChukwuemeka Chinedum Udekwu
Chukwuemeka Chinedum Udekwu
OOOluwatosin Qawiyy Orababa
Oluwatosin Qawiyy Orababa
AKAyomikun Emmanuel Kade
Ayomikun Emmanuel Kade
Desmoglein-2 (DSG2) has emerged as a potential biomarker for coronavirus disease 2019 (COVID-19) complications, particularly cardiac and cardiovascular involvement. The expression of DSG2 in lung tissues has been detected at elevated levels, and circulating DSG2 levels correlate with COVID-19 severity. DSG2 may contribute to myocardial injury, cardiac dysfunction and vascular endothelial dysfunction in COVID-19. Monitoring DSG2 levels could aid in risk stratification, early detection and prognostication of COVID-19 complications. However, further research is required to validate DSG2 as a biomarker. Such research will aim to elucidate its precise role in pathogenesis, establishing standardized assays for its measurement and possibly identifying therapeutic targets.

18 September 2025 in bioRxiv
Verified
Preprint
Open access
ATAfifah Tasnim
Afifah Tasnim
LMLauren A. M. Murray
Lauren A. M. Murray
RCRebecca A. Clayton
Rebecca A. Clayton
CUChidiebere F. Uchechukwu
Chidiebere F. Uchechukwu
JZJinlian Zhao
Jinlian Zhao
NRNicole C. Robb
Nicole C. Robb
Summary: The influenza virus is a leading cause of respiratory tract infection in humans, with the emergence of antiviral drug resistance posing an ongoing challenge to the treatment of influenza. This underscores the urgent need for effective new antiviral treatments. Spirotetronates are a family of bacterial natural products with a range of potent bioactivities. Some members of this family have antiviral activity. Here, we report the bioinformatics-based stereochemical assignment, antiviral properties, and mechanism of action of the unusual type II spirotetronate MM 46115 (renamed pellemicin). We show that pellemicin is active against both influenza A and B viruses at non-toxic concentrations, and inhibits clathrin-mediated endocytosis, which is required for virus internalisation. Given the need for new treatments for viral infections, the results of our work suggest that pellemicin and related spirotetronates could provide a basis for developing promising alternatives to existing antivirals to combat drug-resistant influenza. Graphical Highlights: MM 46115 (here renamed pellemicin) produced by a mycetoma pathogen is a promising antiviral The pellemicin biosynthetic gene cluster was identified in Actinomadura pelletieri DSM 43383 Sequence analysis of biosynthetic enzymes enabled full stereochemical assignment Pellemicin inhibits clathrin-mediated endocytosis, an early stage of the viral life cycle Significance: The influenza virus is a respiratory pathogen with epidemic and pandemic potential, resulting in tens of thousands of deaths each year and causing significant health, social and economic impact. The rise of resistant influenza strains against existing antiviral drugs creates a pressing need for alternative treatments. Natural products - specialised metabolites of bacteria, fungi, and plants that often have antimicrobial activity - are a promising source of therapeutics to treat human disease. Here, we identify a cryptic polyketide biosynthetic gene cluster in the genome sequence of Actinomadura pelletieri DSM 43383, an Actinomycete that causes mycetoma in humans. This is proposed to direct production of the previously reported spirotetronate MM 46115 (here renamed pellemicin), which has activity against the influenza virus. Sequence analyses of a polyketide synthase and Diels-Alderase involved in pellemicin biosynthesis, combined with comparative analysis of NMR data for other spirotetronates, enabled us to fully resolve longstanding stereochemical ambiguities in the structure of pellemicin. This underscores the emerging power of bioinformatics-based approaches, and their complementarity to traditional spectroscopic methods, for natural product structure elucidation. We also report extensive insights into the antiviral properties and mechanism of pellemicin, demonstrating that it exhibits antiviral activity at non-toxic doses for up to eight hours after administration and inhibits clathrin-mediated endocytosis, a process that many viruses exploit to enter cells. Only one other bacterial natural product, ikarugamycin, is known to inhibit clathrin-mediated endocytosis. Ikarugamycin contains a tetramate group, which bears a close structural relationship to the tetronate moiety of pellemicin, suggesting that inhibition of clathrin-mediated endocytosis may be a general mechanism of action for antiviral spirotetronates. Our findings therefore indicate that pellemicin, and related spirotetronate natural products, could form a basis for development of new drugs to combat antiviral resistance, and serve as useful tools to study the process of endocytosis.

11 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
OOOluwatosin Qawiyy Orababa
Oluwatosin Qawiyy Orababa
CCCharlotte Cornbill
Charlotte Cornbill
AKAyomikun Kade
Ayomikun Kade
CUChidiebere F. Uchechukwu
Chidiebere F. Uchechukwu
Shristi SharmaShristi Sharma
Shristi Sharma
FHFreya Harrison
Freya Harrison
Pseudomonas aeruginosa remains one of the most important clinical pathogens for which new drugs are needed, due to its resistance machinery. Consequently, there is an increasing effort to develop new and effective treatments against this pathogen. We recently showed that tetrasodium ethylenediaminetetraacetic acid (tEDTA) exhibits promising antibacterial and antibiofilm activity against P. aeruginosa in advanced biofilm models. tEDTA is known to chelate divalent cations, with predicted effects on the outer membrane; however, a full understanding of how this kills P. aeruginosa is lacking. Also, it is currently not clear how slowly or rapidly P. aeruginosa will evolve resistance to this treatment. Using membrane disruption assays and RNA-seq, we showed that tEDTA disrupts bacterial membrane potential and permeabilises P. aeruginosa membranes. RNA-seq revealed the significant upregulation of genes involved in the transport of iron, phosphate, potassium, and magnesium ion. The arnABCD operon which is involved in lipid A biosynthesis was also upregulated. Using a 7-day evolutionary ramp approach, we showed that P. aeruginosa could not evolve resistance to tEDTA under strong selection. Lastly, we carried out a cytotoxicity assay with Human Epithelial type 2 (HEp-2) cells and showed that there was reduced cytotoxicity of tEDTA compared to meropenem. This study provides good insight into the mechanism of action of tEDTA and further evidence of its potential as an alternative to antibiotics for P. aeruginosa infections.